Galectin Therapeutics Inc. (GALT)Healthcare | Biotechnology | Norcross, United States | NasdaqCM
4.60 USD
+0.54
(13.301%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 4.51 -0.09 (-0.089%) ⇩ (July 13, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:45 a.m. EDT
The immediate outlook is driven by a massive speculative squeeze rather than fundamental value. With the stock trading near its 52-week low and a negative book value, the business fundamentals are precarious, yet the options chain screams 'breakout.' The overwhelming call open interest at the $5.00 strike suggests traders are positioning for a rapid move away from the current $4.06 range, likely fueled by the recent FDA trial agreement news. This creates a high-risk, high-reward scenario where the stock could surge on momentum or get crushed if volume dries up. For the long term, the picture is murky; the company burns cash, has no dividend, and faces the typical risks of biotech development. While the multi-year price trajectory shows a net gain, the lack of consistent profitability and the heavy reliance on one-off events prevent a confident buy recommendation for a buy-and-hold strategy. The current setup is a classic momentum play, not a value investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.121983 |
| AutoARIMA | 0.124815 |
| AutoETS | 0.124829 |
| MSTL | 0.125607 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 18% |
| H-stat | 30.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 4.08 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 302,941,728 |
| Forward P/E | -2.74 |
| Beta | 0.35 |
| Previous Name | Galectin Therapeutics, Inc. |
| Website | https://galectintherapeutics.com |
As of July 11, 2026, 2:45 a.m. EDT: Speculators are overwhelmingly bullish, with open interest heavily skewed toward calls (98% OTM positioning) compared to negligible put activity. The strike distribution shows massive concentration at the $5.00 level across near-term expirations, suggesting a collective bet on a breakout above current prices. However, the implied volatility surface is extremely compressed (under 2%), indicating a lack of pricing for significant moves despite the heavy positioning.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.42456138 |
| Address1 | 4,960 Peachtree Industrial Boulevard |
| Address2 | Suite 240 |
| All Time High | 38.28 |
| All Time Low | 0.3 |
| Ask | 5.19 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,305,610 |
| Average Daily Volume3 Month | 589,485 |
| Average Volume | 589,485 |
| Average Volume10Days | 1,305,610 |
| Beta | 0.353 |
| Bid | 3.46 |
| Bid Size | 2 |
| Book Value | -2.011 |
| City | Norcross |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.6 |
| Current Ratio | 2.147 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.82 |
| Day Low | 4.01 |
| Display Name | Galectin Therapeutics |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 429,728,736 |
| Eps Forward | -1.68 |
| Eps Trailing Twelve Months | -0.41 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9234 |
| Fifty Day Average Change | 1.6766 |
| Fifty Day Average Change Percent | 0.5735103 |
| Fifty Two Week Change Percent | 42.45614 |
| Fifty Two Week High | 7.13 |
| Fifty Two Week High Change | -2.5300002 |
| Fifty Two Week High Change Percent | -0.35483873 |
| Fifty Two Week Low | 2.03 |
| Fifty Two Week Low Change | 2.57 |
| Fifty Two Week Low Change Percent | 1.2660098 |
| Fifty Two Week Range | 2.03 - 7.13 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,031,146,200,000 |
| Float Shares | 47,187,126 |
| Forward Eps | -1.68 |
| Forward P E | -2.7380953 |
| Free Cashflow | -18,666,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.29088 |
| Held Percent Institutions | 0.21172 |
| Implied Shares Outstanding | 65,856,898 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,332,460,800 |
| Last Split Factor | 1:6 |
| Long Business Summary | Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. |
| Long Name | Galectin Therapeutics Inc. |
| Market | us_market |
| Market Cap | 302,941,728 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1065415 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -26,436,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 267,379,005 |
| Number Of Analyst Opinions | 1 |
| Open | 4.011 |
| Operating Cashflow | -20,052,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | -36.15 |
| Phone | 678 620 3186 |
| Post Market Change | -0.08920002 |
| Post Market Change Percent | -1.9391309 |
| Post Market Price | 4.5108 |
| Post Market Time | 1,783,986,818 |
| Prev Name | Galectin Therapeutics, Inc. |
| Previous Close | 4.06 |
| Price Hint | 4 |
| Price To Book | -2.2874193 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.931 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.54 |
| Regular Market Change Percent | 13.3005 |
| Regular Market Day High | 4.82 |
| Regular Market Day Low | 4.01 |
| Regular Market Day Range | 4.01 - 4.82 |
| Regular Market Open | 4.011 |
| Regular Market Previous Close | 4.06 |
| Regular Market Price | 4.6 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,369,353 |
| Return On Assets | -0.80402 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 65,856,898 |
| Shares Percent Shares Out | 0.1362 |
| Shares Short | 8,972,735 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,663,672 |
| Short Name | Galectin Therapeutics Inc. |
| Short Percent Of Float | 0.2138 |
| Short Ratio | 8.85 |
| Source Interval | 15 |
| State | GA |
| Symbol | GALT |
| Target High Price | 11.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 14,111,000 |
| Total Cash Per Share | 0.214 |
| Total Debt | 138,695,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.7071 |
| Two Hundred Day Average Change | 0.8929 |
| Two Hundred Day Average Change Percent | 0.24086213 |
| Type Disp | Equity |
| Volume | 1,369,353 |
| Website | https://galectintherapeutics.com |
| Zip | 30,071 |